UroGen Pharma (URGN) Stock Price, News & Analysis $14.10 -0.17 (-1.19%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$13.93▼$14.3550-Day Range$10.87▼$14.4452-Week Range$7.15▼$24.13Volume34,610 shsAverage Volume310,370 shsMarket Capitalization$330.65 millionP/E RatioN/ADividend YieldN/APrice Target$37.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability UroGen Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside162.4% Upside$37.00 Price TargetShort InterestBearish12.07% of Shares Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.54) to ($2.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector657th out of 942 stocksPharmaceutical Preparations Industry304th out of 424 stocks 3.3 Analyst's Opinion Consensus RatingUroGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.00, UroGen Pharma has a forecasted upside of 162.4% from its current price of $14.10.Amount of Analyst CoverageUroGen Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.07% of the outstanding shares of UroGen Pharma have been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in UroGen Pharma has recently increased by 23.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for UroGen Pharma is -1.33. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.13% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.42% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for UroGen Pharma are expected to grow in the coming year, from ($3.54) to ($2.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About UroGen Pharma Stock (NASDAQ:URGN)UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Read More URGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart URGN Stock News HeadlinesNovember 27, 2023 | finance.yahoo.comShareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years agoNovember 15, 2023 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call TranscriptDecember 11, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | markets.businessinsider.comUroGen Pharma Ltd. Q3 Loss decreases, beats estimatesNovember 14, 2023 | finance.yahoo.comUroGen Pharma Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comUroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical TrialsNovember 13, 2023 | benzinga.comPreview: UroGen Pharma's EarningsNovember 13, 2023 | finance.yahoo.comUroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic OncologyDecember 11, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 12, 2023 | nasdaq.comUroGen Pharma (FRA:UR8) Price Target Increased by 29.89% to 36.83November 7, 2023 | finance.yahoo.comUroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023October 30, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 50% in UroGen Pharma Ltd. (NASDAQ:URGN)October 4, 2023 | markets.businessinsider.comPromising Clinical Progress and Profitability Prospects: An In-depth Analysis of Urogen Pharma’s UGN-102October 4, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for UroGen PharmaOctober 3, 2023 | markets.businessinsider.comUroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024August 18, 2023 | finance.yahoo.comUroGen Pharma (URGN) Stock Surges 89% in a Month: Here's WhyAugust 18, 2023 | fool.comUroGen Pharma (NASDAQ: URGN)August 17, 2023 | finance.yahoo.comNew Treatment for Bladder Cancer Offers This Biotech a Second ChanceAugust 12, 2023 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call TranscriptAugust 12, 2023 | markets.businessinsider.comGoldman Sachs Remains a Hold on Urogen Pharma (URGN)August 10, 2023 | markets.businessinsider.comUroGen Pharma Ltd. Q2 Loss decreases, beats estimatesAugust 10, 2023 | finance.yahoo.comWall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a BetAugust 10, 2023 | finance.yahoo.comUroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate DevelopmentsAugust 8, 2023 | finance.yahoo.comThe Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerAugust 3, 2023 | finance.yahoo.comUroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023August 2, 2023 | msn.comHC Wainwright & Co. Maintains UroGen Pharma (URGN) Buy RecommendationAugust 2, 2023 | msn.comUroGen Pharma (URGN) Price Target Increased by 22.33% to 32.13See More Headlines Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:URGN CUSIPN/A CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees192Year FoundedN/APrice Target and Rating Average Stock Price Target$37.00 High Stock Price Target$54.00 Low Stock Price Target$10.00 Potential Upside/Downside+162.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,780,000.00 Net Margins-135.20% Pretax Margin-135.03% Return on EquityN/A Return on Assets-77.74% Debt Debt-to-Equity RatioN/A Current Ratio7.06 Quick Ratio6.87 Sales & Book Value Annual Sales$64.36 million Price / Sales5.14 Cash FlowN/A Price / Cash FlowN/A Book Value($3.93) per share Price / Book-3.59Miscellaneous Outstanding Shares23,450,000Free Float20,844,000Market Cap$330.65 million OptionableOptionable Beta1.00 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Elizabeth A. Barrett (Age 61)President, CEO & Director Comp: $1.12MMr. Dong Kim (Age 46)Chief Financial Officer Comp: $546.68kMr. Jason Drew Smith (Age 51)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $717.58kVincent I. PerroneSenior Director of Investor RelationsMr. Bryon WornsonExecutive Vice President of Talent, Advocacy & CommunicationsDr. Sari Prutchi-Sagiv Ph.D.Marketing DirectorDr. Marina KonortyExecutive Vice President of Research & Development and Technical OperationsDr. Mark P. Schoenberg M.D. (Age 65)Chief Medical Officer Comp: $579.5kMr. Jeffrey Bova M.B.A.Chief Commercial OfficerMr. James Ottinger R.ph.Executive Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsGeneluxNASDAQ:GNLXKalVista PharmaceuticalsNASDAQ:KALVFulcrum TherapeuticsNASDAQ:FULCGH ResearchNASDAQ:GHRSPrecigenNASDAQ:PGENView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 70,063 shares on 12/1/2023Ownership: 0.299%Deutsche Bank AGBought 9,143 shares on 11/24/2023Ownership: 0.045%Ameriprise Financial Inc.Bought 1,069 shares on 11/15/2023Ownership: 0.367%Annandale Capital LLCSold 2,500 shares on 11/15/2023Ownership: 0.349%GSA Capital Partners LLPBought 10,189 shares on 11/15/2023Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions URGN Stock Analysis - Frequently Asked Questions Should I buy or sell UroGen Pharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" URGN shares. View URGN analyst ratings or view top-rated stocks. What is UroGen Pharma's stock price target for 2024? 3 Wall Street research analysts have issued 1 year target prices for UroGen Pharma's stock. Their URGN share price targets range from $10.00 to $54.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 162.4% from the stock's current price. View analysts price targets for URGN or view top-rated stocks among Wall Street analysts. How have URGN shares performed in 2023? UroGen Pharma's stock was trading at $8.87 at the beginning of the year. Since then, URGN shares have increased by 59.0% and is now trading at $14.10. View the best growth stocks for 2023 here. Are investors shorting UroGen Pharma? UroGen Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,830,000 shares, an increase of 23.6% from the October 31st total of 2,290,000 shares. Based on an average daily volume of 248,800 shares, the days-to-cover ratio is currently 11.4 days. View UroGen Pharma's Short Interest. When is UroGen Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our URGN earnings forecast. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) announced its earnings results on Tuesday, November, 14th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.21. The firm earned $20.85 million during the quarter, compared to analysts' expectations of $19.80 million. What ETF holds UroGen Pharma's stock ? ARK Israel Innovative Technology ETF holds 218,434 shares of URGN stock, representing 1.96% of its portfolio. What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU). When did UroGen Pharma IPO? (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are UroGen Pharma's major shareholders? UroGen Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.33%), Harel Insurance Investments & Financial Services Ltd. (3.71%), Migdal Insurance & Financial Holdings Ltd. (2.76%), Silverarc Capital Management LLC (2.17%), Laurion Capital Management LP (1.62%) and Clal Insurance Enterprises Holdings Ltd (0.95%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg and Molly Henderson. View institutional ownership trends. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:URGN) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.